



OFFICE OF THE UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

FORCE RESILIENCY

JAN 10 2019

MEMORANDUM FOR SECRETARY OF THE ARMY  
SECRETARY OF THE NAVY  
SECRETARY OF THE AIR FORCE

SUBJECT: Termination of the Use of the Social Security Number in the Military Personnel Drug Abuse Testing Program

Effective immediately, the Electronic Data Interchange Person Identifier (EDI-PI) will be the primary means of sample identification in the Military Drug Abuse Testing Program (MDATP). This policy change is necessary to satisfy the requirements of DoDI 1000.30, "Reduction of Social Security Number (SSN) Use Within the DoD."

The MDATP initiated the transition from the use of the SSN to the EDI-PI as the primary means of sample identification on March 1, 2015. A detailed transition plan was developed to guide the migration to the use of the EDI-PI. This transition required significant modifications to the Forensic Toxicology Drug Testing Laboratory – Information Management System (FTDTL-IMS), the overarching system that manages the selection, collection, testing, and reporting of drug testing results for the Military Services. The modifications are complete and the FTDTL-IMS is ready.

Starting February 1, 2019, specimens arriving at the Military drug testing laboratories using the SSN for identification will be assigned the discrepancy "IT – SSN Received as DoD ID" and will be tested. Starting on January 1, 2020, specimens received without the EDI-PI for which exemptions have not been granted, as described herein, will no longer be tested and will receive the discrepancy "IN – SSN Received as DoD ID." Services should use the 12-month grace period to ensure adoption of the EDI-PI. In the limited situations where individuals being tested under the auspices of the MDATP are not assigned an EDI-PI, use of the SSN will be authorized. Services must submit a request to exempt such individuals by unit identifier to the Director, Office of Drug Demand Reduction, to cover these situations.

Please direct questions to CAPT Eric R. Welsh, Director, Office of Drug Demand Reduction, at (703) 697-8690, or by email at [eric.r.welsh2.mil@mail.mil](mailto:eric.r.welsh2.mil@mail.mil).

A handwritten signature in black ink, appearing to read "Elizabeth P. Van Winkle", is located below the text.

Elizabeth P. Van Winkle, Ph.D.  
Executive Director, Force Resiliency

cc:

Director, Army Substance Abuse Program

Director, Navy Drug Detection and Deterrence Branch

Army Drug Testing Program Manager

Navy Drug Testing Program Manager

Air Force Drug Testing Program Manager

Marine Corps Drug Demand Reduction Program

Army National Guard Substance Abuse Program Manager

Chief, Drug Demand Reduction Program, Air National Guard Bureau

Chief, Army Reserve Substance Abuse Program

Chief, Division of Forensic Toxicology, Armed Forces Medical Examiner System

Commander, U.S. Military Entrance Processing Command